Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_11335 details
Primary information
SALIDSAL_11335
Biomarker nameInterleukin 7
Biomarker TypeDiagnostic
Sampling MethodBMS patients and controls were diagnosed according to the International Headache society criteria.
Collection MethodStimulated whole saliva (SWS) was collected from the patients with BMS and the controls
Analysis MethodELISA
Collection SiteWhole Saliva
Disease CategoryOther
Disease/ConditionBurning mouth Syndrome
Disease SubtypeNA
Fold Change/ ConcentrationNA
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID31414088
Year of Publication2019
Biomarker IDA8K673
Biomarker CategoryProtein
SequenceMFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDSKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH
Title of studyReduced sialyl-Lewis(x) on salivary MUC7 from patients with burning mouth syndrome
Abstract of studyWe analysed and compared MUC7 O-glycosylation and inflammatory biomarkers in saliva from female patients with burning mouth syndrome (BMS) and gender/age-matched controls. Oligosaccharides from salivary MUC7 from BMS and controls were released. Inflammatory mediators were measured by multiplex proximity extension assay. Presence of sialyl-Lewisx (Si-Lex) epitope on MUC7 was confirmed using Western blot. MUC7 O-glycans and measured inflammatory biomarkers were found to be similar between BMS and controls. However, oligosaccharides sialyl-Lewisx (Si-Lex) was found to be reduced in samples from BMS patients. Positive correlation (combined patients and controls) was found between levels of C-C motif chemokine 19 (CCL-19) and the amount of core-2 oligosaccharides on MUC7 as well as fractalkine (CX3CL1) and level of sialylation. Patients with BMS were shown to represent a heterogeneous group in terms of inflammatory biomarkers. This indicates that BMS patients could be further stratified on the basis of low-level inflammation. The results furthermore indicate that reduced sialylation of MUC7, particularly Si-Lex, may be an important feature in patients with BMS. However, the functional aspects and potential involvement in immune regulation of Si-Lex remains unclear. Our data suggests a chemokine driven alteration of MUC7 glycosylation.